Published in Pharmacogenet Genomics on January 01, 2011
PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol (2013) 1.81
Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist (2012) 1.50
A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy. Int J Mol Sci (2015) 0.82
Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts. Int J Mol Med (2016) 0.75
Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. Handb Exp Pharmacol (2016) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg (2005) 7.36
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med (1998) 3.66
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res (1998) 3.65
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci (2007) 2.15
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res (2007) 1.94
Bisphosphonates: from bench to bedside. Ann N Y Acad Sci (2006) 1.82
Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol (2006) 1.80
Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res (1997) 1.72
Organic anion transport is the primary function of the SLC17/type I phosphate transporter family. Pflugers Arch (2003) 1.71
Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res (2000) 1.70
Antitumor effects of bisphosphonates. Cancer (2003) 1.66
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int (2005) 1.61
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med (2009) 1.56
Bisphosphonate mechanism of action. Curr Rheumatol Rep (2003) 1.39
Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol (2002) 1.38
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet (2005) 1.37
Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol (2006) 1.37
Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res (1998) 1.36
An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int (1997) 1.34
Pharmacokinetics of alendronate. Clin Pharmacokinet (1999) 1.31
Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope (2006) 1.30
The acute-phase response after bisphosphonate administration. Calcif Tissue Int (1987) 1.29
Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev (2008) 1.29
Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res (1992) 1.28
Bisphosphonate mechanism of action. Curr Mol Med (2002) 1.20
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone (1996) 1.14
Bisphosphonates and cancer. J Vet Intern Med (2004) 1.02
The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int (2002) 1.00
The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol (2005) 0.97
The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 0.91
Genetics and pharmacogenetics of osteoporosis. J Endocrinol Invest (2005) 0.90
LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men. Calcif Tissue Int (2009) 0.88
Pharmacogenomics of osteoporosis: opportunities and challenges. J Musculoskelet Neuronal Interact (2006) 0.87
VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos Int (1999) 0.87
COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int (2002) 0.86
Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf) (2003) 0.86
No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2002) 0.84
Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin (2008) 0.83
Bisphosphonate action: revelations and deceptions from in vitro studies. J Pharm Sci (2007) 0.83
Pharmacogenetics of bone treatments: the VDR and ERalpha gene story. Pharmacogenomics (2008) 0.81
Pharmacogenetics of osteoporosis and the prospect of individualized prognosis and individualized therapy. Curr Opin Endocrinol Diabetes Obes (2008) 0.81
Interaction of Alkyl/Arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule. J Pharmacol Exp Ther (1997) 0.80
Pharmacogenetics of osteoporosis: future perspectives. Calcif Tissue Int (2009) 0.80
1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung (1996) 0.80
Bisphosphonate actions on cancer. Calcif Tissue Int (2003) 0.79
Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone. Calcif Tissue Int (2008) 0.77
-511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone. Bone (2005) 0.77
Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32
Clinical assessment incorporating a personal genome. Lancet (2010) 10.18
The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science (2008) 8.52
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Genetics. Genomic research and human subject privacy. Science (2004) 6.56
PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res (2002) 6.40
A Bayesian framework for combining heterogeneous data sources for gene function prediction (in Saccharomyces cerevisiae). Proc Natl Acad Sci U S A (2003) 6.19
From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med (2011) 4.05
Knowledge acquisition, consistency checking and concurrency control for Gene Ontology (GO). Bioinformatics (2003) 3.97
SAFA: semi-automated footprinting analysis software for high-throughput quantification of nucleic acid footprinting experiments. RNA (2005) 3.95
Associating genes with gene ontology codes using a maximum entropy analysis of biomedical literature. Genome Res (2002) 3.77
Nonparametric methods for identifying differentially expressed genes in microarray data. Bioinformatics (2002) 3.65
Health-information altruists--a potentially critical resource. N Engl J Med (2005) 3.61
The RNA Ontology Consortium: an open invitation to the RNA community. RNA (2006) 3.60
Creating an online dictionary of abbreviations from MEDLINE. J Am Med Inform Assoc (2002) 3.32
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet (2011) 3.20
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Data-driven prediction of drug effects and interactions. Sci Transl Med (2012) 2.93
Challenges in the clinical application of whole-genome sequencing. Lancet (2010) 2.92
Eukaryotic regulatory element conservation analysis and identification using comparative genomics. Genome Res (2004) 2.84
PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet (2007) 2.65
Coarse-grained modeling of large RNA molecules with knowledge-based potentials and structural filters. RNA (2009) 2.63
A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc (2011) 2.53
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52
The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res (2007) 2.45
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Bioinformatics challenges for personalized medicine. Bioinformatics (2011) 2.28
Time to organize the bioinformatics resourceome. PLoS Comput Biol (2005) 2.25
MScanner: a classifier for retrieving Medline citations. BMC Bioinformatics (2008) 2.24
Using binning to maintain confidentiality of medical data. Proc AMIA Symp (2002) 2.23
Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc (2013) 2.19
Using text to build semantic networks for pharmacogenomics. J Biomed Inform (2010) 2.19
Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. BMC Bioinformatics (2009) 2.15
PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev (2008) 2.09
GAPSCORE: finding gene and protein names one word at a time. Bioinformatics (2004) 2.05
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Computational analysis of Plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res (2004) 1.92
Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics (2010) 1.91
Recent progress in automatically extracting information from the pharmacogenomic literature. Pharmacogenomics (2010) 1.88
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Automating data acquisition into ontologies from pharmacogenetics relational data sources using declarative object definitions and XML. Pac Symp Biocomput (2002) 1.81
PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol (2013) 1.81
PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Methods Mol Biol (2005) 1.80
High-throughput single-nucleotide structural mapping by capillary automated footprinting analysis. Nucleic Acids Res (2008) 1.78
Using text analysis to identify functionally coherent gene groups. Genome Res (2002) 1.71
The FEATURE framework for protein function annotation: modeling new functions, improving performance, and extending to novel applications. BMC Genomics (2008) 1.64
Challenges for biomedical informatics and pharmacogenomics. Annu Rev Pharmacol Toxicol (2002) 1.61
Finding haplotype tagging SNPs by use of principal components analysis. Am J Hum Genet (2004) 1.61
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
MutDB: annotating human variation with functionally relevant data. Bioinformatics (2003) 1.54
Structural inference of native and partially folded RNA by high-throughput contact mapping. Proc Natl Acad Sci U S A (2008) 1.54
Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics (2011) 1.53
Training the next generation of informaticians: the impact of "BISTI" and bioinformatics--a report from the American College of Medical Informatics. J Am Med Inform Assoc (2004) 1.53
Discovery and explanation of drug-drug interactions via text mining. Pac Symp Biocomput (2012) 1.53
The computational analysis of scientific literature to define and recognize gene expression clusters. Nucleic Acids Res (2003) 1.44
Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships. Hum Mol Genet (2008) 1.42
The functional importance of disease-associated mutation. BMC Bioinformatics (2002) 1.41
Independent component analysis: mining microarray data for fundamental human gene expression modules. J Biomed Inform (2010) 1.39
Local kinetic measures of macromolecular structure reveal partitioning among multiple parallel pathways from the earliest steps in the folding of a large RNA molecule. J Mol Biol (2006) 1.38
Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 1.38
A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge. J Am Med Inform Assoc (2004) 1.37
WebFEATURE: An interactive web tool for identifying and visualizing functional sites on macromolecular structures. Nucleic Acids Res (2003) 1.35
A literature-based method for assessing the functional coherence of a gene group. Bioinformatics (2003) 1.33
A call for the creation of personalized medicine databases. Nat Rev Drug Discov (2006) 1.30
Extracting and characterizing gene-drug relationships from the literature. Pharmacogenetics (2004) 1.30
Using ODIN for a PharmGKB revalidation experiment. Database (Oxford) (2012) 1.29
Integration and publication of heterogeneous text-mined relationships on the Semantic Web. J Biomed Semantics (2011) 1.29
Biomedical term mapping databases. Nucleic Acids Res (2005) 1.29
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics (2011) 1.29
Informatics confronts drug-drug interactions. Trends Pharmacol Sci (2013) 1.28
Turning limited experimental information into 3D models of RNA. RNA (2010) 1.27
Semiautomated and rapid quantification of nucleic acid footprinting and structure mapping experiments. Nat Protoc (2008) 1.27
A new disease-specific machine learning approach for the prediction of cancer-causing missense variants. Genomics (2011) 1.27
PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27
Distinct contribution of electrostatics, initial conformational ensemble, and macromolecular stability in RNA folding. Proc Natl Acad Sci U S A (2007) 1.26
Pharmacogenomics: The relevance of emerging genotyping technologies. MLO Med Lab Obs (2006) 1.26
Predicting drug side-effects by chemical systems biology. Genome Biol (2009) 1.26